Get the Stockscreener App
26.13
1.77%
-0.47
After Hours:
26.13
Castle Biosciences Inc stock is traded at $26.13, with a volume of 232.54K.
It is down -1.77% in the last 24 hours and down -19.20% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
See More
Previous Close:
$26.60
Open:
$26.41
24h Volume:
232.54K
Relative Volume:
0.58
Market Cap:
$776.88M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-12.15
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
-7.24%
1M Performance:
-19.20%
6M Performance:
+14.86%
1Y Performance:
+33.73%
1-Day Range:
$25.82
$26.64
1-Week Range:
$25.76
$28.58
52-Week Range:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
26.13 | 790.85M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
495.72 | 185.77B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
195.06 | 138.05B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
600.52 | 47.68B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
115.42 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
297.54 | 29.39B | 3.17B | 642.63M | 516.49M | 10.77 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences Inc (CSTL) CFO Frank Stokes Sells 6,001 Shares - GuruFocus
Insider Selling: Castle Biosciences (NASDAQ:CSTL) CFO Sells 6,001 Shares of Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Director Sells 7,403 Shares of Stock - MarketBeat
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest - GlobeNewswire
Aug Wrap: Whats next for Castle Biosciences Inc stockVolume Spike & Expert Verified Movement Alerts - baoquankhu1.vn
Death Cross: Will Castle Biosciences Inc benefit from current market trendsEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
How Castle Biosciences (CSTL) Story Is Shifting With New Revenue Targets And Fair Value - Yahoo Finance
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k - Investing.com South Africa
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k By Investing.com - Investing.com India
Frank Stokes Sells 7,000 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences: Interview With Founder, CEO, And President Derek Maetzold About The Molecular Diagnostics Company - Pulse 2.0
Castle Biosciences Stock Hits Day Low of $27.22 Amid Price Pressure - Markets Mojo
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - The Manila Times
Castle Biosciences to Present Data at SSO 2026 on - GlobeNewswire
Castle Biosciences (NASDAQ:CSTL) Lowered to Hold Rating by Zacks Research - MarketBeat
Castle Biosciences to Present Data at SSO 2026 on DecisionDx-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - Bitget
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - Bitget
CSTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Canaccord reiterates Castle Biosciences stock rating on Q4 beat By Investing.com - Investing.com India
Canaccord reiterates Castle Biosciences stock rating on Q4 beat - Investing.com Nigeria
Aug Volume: What is the target price for Seer Inc stockEarnings Beat & Community Shared Stock Ideas - baoquankhu1.vn
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unveiling a Promising 50.96% Upside for Investors - DirectorsTalk Interviews
Castle Biosciences (NASDAQ:CSTL) Shares Gap DownWhat's Next? - MarketBeat
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - Finviz
Castle Biosciences (CSTL) Analyst Rating Update: Baird Raises Pr - GuruFocus
Robert W. Baird Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Expert Outlook: Castle Biosciences Through The Eyes Of 6 Analysts - Benzinga
Castle Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CSTL) 2026-02-27 - Seeking Alpha
Castle Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Transcript : Castle Biosciences, Inc., Q4 2025 Earnings Call, Feb 26, 2026 - marketscreener.com
Castle Biosciences Q4 2025 slides: test volumes surge 42%, enters AD market - Investing.com Nigeria
Volatility Watch: Will Castle Biosciences Inc stock go up in YEAR2025 Bull vs Bear & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results - MarketBeat
Castle Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Castle Biosciences (CSTL) Expects Revenue Growth by 2026 - GuruFocus
Castle Biosciences (CSTL) Earnings Transcript - AOL.com
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Castle Biosciences Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Castle Biosciences Q4 2025 beats expectations, stock rises - Investing.com
Earnings Flash (CSTL) Castle Biosciences, Inc. Reports Q4 Revenue $87.0M, vs. FactSet Est of $79.9M - marketscreener.com
Castle Biosciences Posts Modest 2025 Growth Amid Headwinds - TipRanks
Earnings Flash (CSTL) Castle Biosciences, Inc. Posts Q4 Adjusted Loss $0.08 per Share, vs. FactSet Est of $-0.26 - marketscreener.com
Castle Biosciences Reports 37% Increase in Core Test Reports for 2025, Achieving $344 Million in Revenue - Quiver Quantitative
Castle Biosciences (CSTL) swings to 2025 loss as margins compress - Stock Titan
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Castle Biosciences Stock Hits Day Low of $27.80 Amid Price Pressure - Markets Mojo
Exploring Castle Biosciences's Earnings Expectations - Benzinga
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):